Ensysce Biosciences, Inc. (ENSC) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Ensysce Biosciences, Inc. (ENSC) Healthcare & Pipeline Overview

Ensysce Biosciences, Inc. develops prescription drugs for severe pain relief and to prevent opioid addiction, misuse, abuse, and overdose. The company utilizes Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms to create safer opioid alternatives, addressing a critical need in the healthcare sector.

What Is the Investment Thesis for ENSC?

Ensysce Biosciences presents a notable research candidate due to its innovative approach to addressing the opioid crisis with abuse-resistant and overdose-resistant prodrug technologies. The company's lead candidate, PF614, is in Phase II clinical trials and has the potential to become a safer alternative to traditional opioids for pain management. The MPAR platform offers an additional layer of protection against overdose, further enhancing the value proposition. Key catalysts include the progression of PF614 through clinical trials and potential partnerships for commercialization. However, the company's negative profit margin of -417.1% and gross margin of -72.9% highlight the financial risks associated with a clinical-stage pharmaceutical company. Successful clinical trial outcomes and strategic collaborations are critical for driving long-term value.

Based on FMP financials and quantitative analysis

ENSC Key Highlights

Ensysce Biosciences is a clinical-stage pharmaceutical company focused on developing abuse-resistant and overdose-resistant opioid prodrugs.

• The company's lead product candidate, PF614, is a TAAP prodrug of oxycodone currently in Phase II clinical trials for the treatment of acute and chronic pain.
• Ensysce utilizes Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms to enhance drug safety.
• The company is also developing PF614-MPAR, a combination product for overdose protection, currently in Phase I clinical trials.
• Ensysce's pipeline includes prodrugs for ADHD medication abuse (PF8001 and PF8026) and opioid use disorder (PF26810).

Who Are ENSC's Competitors?

ENSC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ENSC's Key Strengths?

Innovative TAAP and MPAR technology platforms.

• Pipeline of abuse-resistant and overdose-resistant opioid prodrugs.
• Focus on addressing the opioid crisis.
• Experienced management team.

What Are ENSC's Weaknesses?

Clinical-stage company with no approved products.

• High cash burn rate.
• Dependence on successful clinical trial outcomes.
• Small number of employees.

What Could Drive ENSC Stock Higher?

Phase II clinical trial results for PF614.

• Phase I clinical trial results for PF614-MPAR.
• Development of PF329, an extended-release prodrug of hydromorphone.
• Research and development of PF8001 and PF8026 for ADHD medication abuse.
• Research and development of PF26810 for opioid use disorder.

What Are the Key Risks for ENSC?

Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.

• Failure to obtain regulatory approval for their drug candidates.
• Unsuccessful clinical trial outcomes.
• Competition from other pharmaceutical companies.
• Dependence on securing additional funding.
• Product liability lawsuits.

What Are the Growth Opportunities for ENSC?

• Advancement of PF614 through Clinical Trials: The successful completion of Phase II and Phase III clinical trials for PF614 will be a major growth driver. Positive results demonstrating efficacy and safety could lead to regulatory approval and commercialization. The market for non-abuse-deterrent opioids was estimated to be worth billions of dollars, suggesting a significant potential market for a safer alternative like PF614. Timeline: Anticipated Phase III trial completion within the next 2-3 years.
• Development and Commercialization of PF614-MPAR: The combination of PF614 with nafamostat for overdose protection offers a unique value proposition. Successful development and commercialization of PF614-MPAR could capture a significant share of the overdose prevention market. The increasing awareness and concern about opioid overdoses are driving demand for overdose reversal agents and prevention strategies. Timeline: Potential market entry within 3-5 years, pending clinical trial outcomes and regulatory approvals.
• Expansion of Pipeline with PF329 and Other Prodrugs: The development of PF329, an extended-release prodrug of hydromorphone, and other prodrugs for ADHD and opioid use disorder, diversifies Ensysce's product portfolio and reduces its reliance on a single product. These additional product candidates could address unmet needs in different therapeutic areas and expand the company's market reach. Timeline: Ongoing research and development with potential clinical trials commencing within the next 1-2 years.
• Partnerships and Collaborations: Strategic partnerships with pharmaceutical companies or research institutions could provide Ensysce with additional funding, expertise, and resources to accelerate the development and commercialization of its product candidates. Collaborations could also facilitate access to new markets and distribution channels. The biotechnology industry is characterized by collaborations and partnerships to share risks and rewards. Timeline: Ongoing efforts to establish partnerships and collaborations.
• Nafamostat for Coronaviral and Pulmonary Diseases: The exploration of nafamostat as an oral and inhalation drug product for coronaviral infections and other pulmonary diseases represents a potential new growth area for Ensysce. While this is outside the company's core focus on pain management and addiction treatment, it could provide a new revenue stream and diversify its business. The market for antiviral and pulmonary disease treatments is substantial and growing. Timeline: Ongoing research and development with potential clinical trials commencing within the next 1-2 years.

What Are ENSC's Competitive Advantages?

• Proprietary TAAP and MPAR technology platforms create a barrier to entry for competitors.
• Patent protection for their drug candidates provides exclusivity and market protection.
• Clinical trial data demonstrating the safety and efficacy of their products enhances their competitive position.
• First-mover advantage in the development of abuse-resistant and overdose-resistant opioid prodrugs.

What Does ENSC Do?

Ensysce Biosciences, Inc., founded in La Jolla, California, is a clinical-stage pharmaceutical company dedicated to developing innovative solutions for pain management and preventing opioid abuse and overdose. The company's core focus is on creating a new generation of opioid prodrugs that are both abuse-resistant and overdose-resistant, addressing the growing opioid crisis in the United States. Ensysce utilizes two primary technology platforms: Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR). The TAAP platform is designed to prevent abuse by requiring the drug to be activated by trypsin, an enzyme found in the small intestine, making it difficult to abuse through snorting or injecting. The MPAR platform provides overdose protection by combining the opioid prodrug with a trypsin inhibitor, preventing the release of the opioid if too many pills are ingested. The company's lead product candidate, PF614, is a TAAP prodrug of oxycodone currently in Phase II clinical trials for treating acute and chronic pain. PF614-MPAR, a combination of PF614 and nafamostat, is in Phase I clinical trials for overdose protection. Ensysce is also developing PF329, an extended-release prodrug of hydromorphone, similar to PF614. Additionally, the company is working on PF8001 and PF8026, extended and immediate-release prodrugs of amphetamine for ADHD medication abuse, and PF26810, an extended-release prodrug of methadone for opioid use disorder. Ensysce is also exploring the use of nafamostat as an oral and inhalation drug product for coronaviral infections and other pulmonary diseases, such as cystic fibrosis, further diversifying its pipeline.

What Products and Services Does ENSC Offer?

• Develop abuse-resistant opioid prodrugs using the Trypsin Activated Abuse Protection (TAAP) platform.
• Develop overdose-resistant opioid prodrugs using the Multi-Pill Abuse Resistance (MPAR) platform.
• Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
• Seek regulatory approval from the FDA for their drug candidates.
• Commercialize their approved drug products through partnerships or direct sales.
• Research and develop new drug candidates for pain management, addiction treatment, and other therapeutic areas.

How Does ENSC Make Money?

• Develops pharmaceutical products focused on pain management and addiction.
• Generates revenue through potential future sales of approved drugs.
• Out-licenses or partners with other pharmaceutical companies for commercialization.
• Funds research and development through venture capital and grants.

What Industry Does ENSC Operate In?

Ensysce Biosciences operates within the biotechnology industry, specifically targeting the pain management and addiction treatment markets. The opioid crisis has created a significant need for safer and more effective pain relief options. The market for abuse-resistant opioid formulations is projected to grow as healthcare providers and regulatory agencies seek to reduce opioid-related deaths and addiction rates. Ensysce's TAAP and MPAR technologies position it to compete with other companies developing similar abuse-deterrent formulations, such as Collegium Pharmaceutical and Teva Pharmaceutical Industries. The company's success depends on its ability to navigate the complex regulatory landscape and demonstrate the clinical efficacy and safety of its product candidates.

Who Are ENSC's Key Customers?

• Patients suffering from acute or chronic pain.
• Healthcare providers who prescribe pain medication.
• Pharmacies that dispense pain medication.
• Hospitals and clinics that treat pain and addiction.

How Ensysce Biosciences, Inc. Is Valued

Ensysce Biosciences, Inc. carries a market capitalization of $5.78M, placing it in the micro-cap category. Relative to its peer group, ENSC's quantitative score of 17/100 is below the peer average of 70/100.

Company Profile

Ensysce Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in La Jolla, US. The company is led by CEO D. Lynn Kirkpatrick. ENSC has traded publicly since 2018.

Ensysce Biosciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Ensysce Biosciences, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 26.4% above estimates on average.

Wall Street analysts project Ensysce Biosciences, Inc. revenue of about $7.3M for fiscal 2026, with EPS near $-1.53.

ENSC Financials

ENSC Latest News

ENSC Analyst Consensus

ENSC MoonshotScore

Ensysce Biosciences, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources